The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]

Recruiting

Brief Summary: This protocol is a molecular screening protocol only. No drug intervention study will be included in this protocol. Based on the molecular profiling, patients may be eligible for drug intervention study of SUKSES trial.

This procedure can be performed during or after the first-line treatment. DNA will be extracted from the archived or fresh tissue and blood. NGS-based cancer panel and Nanostring CNV will be tested with DNA from tissue and/or blood.

Immunohistochemistry and FISH will be done by pathologists using archived or fresh tissue.

Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH.

Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.

Detailed Description: This protocol is a molecular screening protocol only. No drug intervention study will be included in this protocol. Based on the molecular profiling, patients may be eligible for drug intervention study of SUKSES trial.

This procedure (molecular profiling) can be performed before, during, or after the initial treatment.

DNA will be extracted from the archived or fresh tissue and blood. NGS-based cancer panel and Nanostring CNV will be tested with DNA from tissue and/or blood.

Immunohistochemistry and FISH will be done by pathologists using archived or fresh tissue.

In addition, blood collection will be conducted at Baseline (initial), three weeks, six weeks, twelve weeks, and subsequent imaging.

Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH. Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.

Recruitment & Eligibility

Inclusion Criteria

Provision of fully informed consent prior to any study specific procedures.
Patients must be ≥20 years of age.
Histologically or cytologically confirmed Small cell lung cancers
ECOG performance status of 0 to 2
Patients who are being treated or were treated with platinum-based chemotherapy as a first-line treatment
Patients with available archival tissues for molecular analysis or patients who agreed with biopsy for molecular analysis

Exclusion Criteria

More than two prior chemotherapy regimen for the treatment of small cell lung cancer
Pregnant or nursing women (women of reproductive potential have to agree to use an effective contraceptive method)
Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤2 years.

Arm && Interventions

Group	Intervention	Description
Small cell lung cancers	No treatment is included in this protocol.	To provide molecular characteristics of Small cell lung cancers to proceed SUKSES trial, To assess success rate of molecular profiling of Small cell lung cancers

Primary Outcome Measures

Name	Time	Method
Ratio of each molecular subtypes	After registration of this study	To provide molecular characteristics of SCLC to proceed SUKSES trial

Secondary Outcome Measures

Name	Time	Method
Success rate of each molecular profiling methods	After completion of registration	To provide molecular characteristics of SCLC to proceed SUKSES trial

Locations (6): Ulsan University Hospital
🇰🇷
Ulsan, Korea, Republic of
Chungbuk University Hospital
🇰🇷
Chungbuk, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷
Incheon, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷
Seongnam, Korea, Republic of
Samsung Medical Center
🇰🇷
Seoul, Korea, Republic of
VHS Medical Center
🇰🇷
Seoul, Korea, Republic of